SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 4,437,869 shares of common stock at $1.69 per share for gross proceeds of approximately $7.5 million. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering. The securities described above publi ...

– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m. EST REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, plans to host a webcast to report 52-week LUNA phase 2 clinical data and 4-year OPTIC clinical data, and to provide key pivotal program design elements Monday, November ...

LAS VEGAS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Full House Resorts, Inc. (Nasdaq: FLL) (the “Company”) today announced that it has named Jeff Michie as vice president and general manager of its Rising Star Casino Resort in Rising Sun, Indiana, subject to customary gaming approvals. Mr. Michie will replace Angi Truebner-Webb who, as previously reported, will become the general manager of the Company’s Silver Slipper Casino Hotel in Hancock County, Mississippi. Mr. Michie joins Rising Star from Casino del Sol, a ...

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Girard Sharp, LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of Qaunterix Corporation (NASDAQ: QTRX) investors. If you are an Quanterix Corporation investor with losses, please fill out this form, email apolk@girardsharp.com, or call (866) 981-4800 for a free consultation. On November 12, 2024, Quanterix announced that it had discovered” an error in the capitalization of labor and ...

NORTH BETHESDA, Md., Nov. 15, 2024 /PRNewswire/ -- Federal Realty Investment Trust (NYSE:FRT) announced today that Jeffrey S. Berkes, the Company's President and Chief Operating Officer, will be leaving the company effective December 31, 2024. Don Wood, Federal's Chief Executive Officer, commented, "Jeff has been my trusted partner and good friend here at Federal for the past 24 years and has been instrumental in growing the company and positioning the company as a leader in the industry. He's one of the fi ...

ST. LOUIS, Nov. 15, 2024 /PRNewswire/ -- Post Holdings, Inc. (NYSE:POST) (the "Company" or "Post") today announced it intends to redeem the remaining $464.9 million in aggregate principal amount of its outstanding 5.625% senior notes due January 2028 (CUSIPS: 737446AN4 and U7318UAN2) (the "2028 Notes") on December 2, 2024 (the "redemption date"). The 2028 Notes will be redeemed at a redemption price of 100.938% of the principal amount thereof, plus the accrued and unpaid interest to, but excluding, the rede ...

ICL Group Ltd (ICL) recorded profits of $113 million or 9 cents per share in third-quarter 2024, down from $137 million or 11 cents in the year-ago quarter. Barring one-time items, adjusted earnings per share were 11 cents. The bottom line beat the Zacks Consensus Estimate of 8 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Sales fell around 6% yearly to $1,753 million in the quarter. The figure beat the Zacks Consensus Estimate of $1,732.7 million.ICL’s Segment HighlightsSales ...

纳斯达克中国金龙指数收涨0.82% 财联社11月16日电，纳斯达克中国金龙指数收涨0.82%，本周累计下 跌5.9%，热门中概股多数上涨，京东涨近5%，名创优品、理想汽车涨超2%，蔚来、新东方涨超1%。 阿里巴巴、爱奇艺跌超2%，哔哩哔哩、知乎跌超1%。 ...

美股三大指数集体收跌 纳指、标普500指数均创9月份以来最大单周跌幅 财联社11月16日电，美股三大 指数集体收跌，纳指跌2.24%，本周累跌3.15%；标普500指数跌1.32%，本周累跌2.08%；道指跌0.7%， 本周累跌1.24%。 其中，纳指、标普500指数均创9月份以来最大单周跌幅，道指创10月下旬以来最大单周跌幅。 大型科技股多数下跌，亚马逊、Meta跌超4%，英伟达跌超3%，微软、英特尔跌逾2%，苹果、奈飞、 谷歌跌超1%；特斯拉涨超3%。 迪士尼涨超5%，本周累涨16.21%，创最近24年来最大单周涨幅。 Palantir涨超11%，创收盘历史新高，该公司即将被纳入纳斯达克。 ...

Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin. 58% ...